Enanta Pharmaceuticals Inc (ENTA) 33.39 $ENTA
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets
Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Positive Data on AbbVie's HCV Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:50PM CDT
AbbVie presented positive data from a global, multi-center, randomized, open-label phase III study, TURQUOISE-II, on its investigational hepatitis C virus (HCV) regimen at the recently held International Liver Congress.
Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting
Business Wire - Sat Apr 12, 12:04AM CDT
--TURQUOISE-II is the largest phase 3, all-oral, Interferon-free study in cirrhotic patients with hepatitis C virus conducted to date
AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress(TM)
PR Newswire - Sat Apr 12, 12:00AM CDT
AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver CongressTM (ILC) 2014. Data from a pivotal phase III study, TURQUOISE-II, featured in the ILC press conference on Friday, will be presented as a late-breaker. Additionally, results from the study have been published online in The New England Journal of Medicine.
Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead Sciences
George Budwell, The Motley Fool - Motley Fool - Fri Apr 11, 7:57AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Enanta Pharmaceuticals and Gilead Sciences AbbVie and Enanta presented additional data from two late-stage studies dubbed SAPPHIRE-I and...
Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting
Business Wire - Fri Apr 11, 12:06AM CDT
--SVR12 rates of 95% to 100% were demonstrated in treatment-experienced GT1 patient sub-populations (SAPPHIRE-II)
AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress(TM)
PR Newswire - Fri Apr 11, 12:00AM CDT
AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference. Results from the pivotal phase III study, SAPPHIRE-II, were also presented at the congress yesterday. Additionally, results from both SAPPHIRE-I and SAPPHIRE-II have been published online in The New England Journal of Medicine.
Merck Hepatitis C Combo Scores 98% Cure Rate
at Investor's Business Daily - Thu Apr 10, 10:48AM CDT
Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with...
Financial Results Announcement, Stock Movement, Presentations, and Acquisition - Analyst Notes on Universal Health Services, Tenet, Cynosure, Albany Molecular Research, and Enanta
PR Newswire - Thu Apr 10, 9:49AM CDT
Today, Analysts Review released its analysts' notes regarding Universal Health Services, Inc. (NYSE: UHS), Tenet Healthcare Corp. (NYSE: THC), Cynosure, Inc. (NASDAQ: CYNO), Albany Molecular Research Inc. (NASDAQ: AMRI), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 7:28AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , Gilead Sciences and Merck & Co. . Bristol-Myers reports strong late-stage results for its hepatitis C drug Bristol-Myers...
Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 8:30AM CDT
The next-generation hepatitis C drug race is rapidly coming to a head with Gilead Sciences ' regulatory filing of its all-oral, once-daily combo pill of Sovaldi plus ledipasvir and the anticipated filing of a New Drug Application for AbbVie and ...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting
Business Wire - Mon Mar 24, 4:05AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced eight studies have been accepted for presentation at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in London April 9-12, 2014. These presentations will report results of regimens containing ABT-450, Enanta's lead protease inhibitor for hepatitis C virus (HCV) identified in its ongoing collaboration with AbbVie. Abstracts can now be viewed at the EASL website at www.easl.eu.
AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress(TM)
PR Newswire - Mon Mar 24, 4:00AM CDT
AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12.
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread
at The Street - Fri Mar 21, 1:02PM CDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.
Gilead's HCV Challengers Near The Starting Gate
at Investor's Business Daily - Wed Mar 19, 7:02AM CDT
Though still in its early days, Gilead Sciences' hepatitis C drug Sovaldi may be enjoying one of the most massive drug launches of all time. Current consensus calls for sales of $4.6 billion this year -- and the whisper numbers are running even...
Has A Streamlined FDA Raised The Value Of Drug Stocks?
at Investor's Business Daily - Thu Apr 17, 4:33PM CDT
Last month, three Democrats from the U.S. Congress sent a now-famous letter to Gilead Sciences (GILD) questioning the $84,000 price of its new blockbuster hepatitis C medicine, Sovaldi. Among the reasons raising suspicions that the price didn't need...
Dr. Reddy's Launches Generic Lunesta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:44AM CDT
Dr. Reddy's Labs announced the launch of its therapeutic equivalent generic version of Sunovion Pharmaceuticals Inc.'s Lunesta tablets
Legal Settlement for Astellas Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 11:41AM CDT
Astellas Pharma announced that it has reached an agreement with the U.S. DOJ to resolve civil claims regarding the marketing of Mycamine for injection
Actelion Beats on Q1 Earnings and Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 10:00AM CDT
Actelion reported 1Q14 earnings of $1.64 per ADR, up 23.6% y/y, beating the Zacks Consensus Estimate of $1.12.
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 8:04AM CDT
Apricus Biosciences, Inc. was a big mover last session, as the company saw its shares rise almost 19% on the day.
Positive Data on AbbVie's HCV Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 3:50PM CDT
AbbVie presented positive data from a global, multi-center, randomized, open-label phase III study, TURQUOISE-II, on its investigational hepatitis C virus (HCV) regimen at the recently held International Liver Congress.
Enanta Pharmaceuticals Announces Detailed Data from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis being Presented at the European Association for the Study of the Liver (EASL) Meeting
Business Wire - Sat Apr 12, 12:04AM CDT
--TURQUOISE-II is the largest phase 3, all-oral, Interferon-free study in cirrhotic patients with hepatitis C virus conducted to date
AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress(TM)
PR Newswire - Sat Apr 12, 12:00AM CDT
AbbVie (NYSE:ABBV) announced that new, detailed results from its hepatitis C development program will be presented today at the International Liver CongressTM (ILC) 2014. Data from a pivotal phase III study, TURQUOISE-II, featured in the ILC press conference on Friday, will be presented as a late-breaker. Additionally, results from the study have been published online in The New England Journal of Medicine.
Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead Sciences
George Budwell, The Motley Fool - Motley Fool - Fri Apr 11, 7:57AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Enanta Pharmaceuticals and Gilead Sciences AbbVie and Enanta presented additional data from two late-stage studies dubbed SAPPHIRE-I and...
Enanta Pharmaceuticals Announces Detailed Data from SAPPHIRE-I and SAPPHIRE-II Phase 3 Studies in Patients with Chronic Hepatitis C Virus Being Presented at the European Association for the Study of the Liver (EASL) Meeting
Business Wire - Fri Apr 11, 12:06AM CDT
--SVR12 rates of 95% to 100% were demonstrated in treatment-experienced GT1 patient sub-populations (SAPPHIRE-II)
AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress(TM)
PR Newswire - Fri Apr 11, 12:00AM CDT
AbbVie (NYSE: ABBV) announced that detailed results from its phase III pivotal study, SAPPHIRE-I, will be presented today at the International Liver Congress(TM) (ILC) 2014 and featured in the ILC press conference. Results from the pivotal phase III study, SAPPHIRE-II, were also presented at the congress yesterday. Additionally, results from both SAPPHIRE-I and SAPPHIRE-II have been published online in The New England Journal of Medicine.
Merck Hepatitis C Combo Scores 98% Cure Rate
at Investor's Business Daily - Thu Apr 10, 10:48AM CDT
Big pharma Merck (MRK) reported stellar results for its phase-two hepatitis C drug trials as the heavy hitters in the field rolled out their latest data Thursday at the International Liver Congress. Merck reported a 98% cure rate in patients with...
Financial Results Announcement, Stock Movement, Presentations, and Acquisition - Analyst Notes on Universal Health Services, Tenet, Cynosure, Albany Molecular Research, and Enanta
PR Newswire - Thu Apr 10, 9:49AM CDT
Today, Analysts Review released its analysts' notes regarding Universal Health Services, Inc. (NYSE: UHS), Tenet Healthcare Corp. (NYSE: THC), Cynosure, Inc. (NASDAQ: CYNO), Albany Molecular Research Inc. (NASDAQ: AMRI), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 7:28AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb , Gilead Sciences and Merck & Co. . Bristol-Myers reports strong late-stage results for its hepatitis C drug Bristol-Myers...
Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist
George Budwell, The Motley Fool - Motley Fool - Wed Apr 09, 8:30AM CDT
The next-generation hepatitis C drug race is rapidly coming to a head with Gilead Sciences ' regulatory filing of its all-oral, once-daily combo pill of Sovaldi plus ledipasvir and the anticipated filing of a New Drug Application for AbbVie and ...
Nasdaq stocks posting largest percentage decreases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting
Business Wire - Mon Mar 24, 4:05AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced eight studies have been accepted for presentation at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in London April 9-12, 2014. These presentations will report results of regimens containing ABT-450, Enanta's lead protease inhibitor for hepatitis C virus (HCV) identified in its ongoing collaboration with AbbVie. Abstracts can now be viewed at the EASL website at www.easl.eu.
AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress(TM)
PR Newswire - Mon Mar 24, 4:00AM CDT
AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12.
Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread
at The Street - Fri Mar 21, 1:02PM CDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.
Gilead's HCV Challengers Near The Starting Gate
at Investor's Business Daily - Wed Mar 19, 7:02AM CDT
Though still in its early days, Gilead Sciences' hepatitis C drug Sovaldi may be enjoying one of the most massive drug launches of all time. Current consensus calls for sales of $4.6 billion this year -- and the whisper numbers are running even...
